Randomized trial of widefield guided PRP for diabetic macular oedema (DMO) treated with Ranibizumab. (Ranibizumab for DMO PRP trial (RDP trial))

Trial Profile

Randomized trial of widefield guided PRP for diabetic macular oedema (DMO) treated with Ranibizumab. (Ranibizumab for DMO PRP trial (RDP trial))

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms RDP trial
  • Sponsors Novartis
  • Most Recent Events

    • 28 Jan 2016 Accrual to date is 54% according to the United Kingdom Clinical Research Network record.
    • 04 Dec 2015 Accrual to date is 50% according to the United Kingdom Clinical Research Network record
    • 05 Oct 2015 Accrual to date is 48% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top